Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Kintor Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Kintor Pharmaceutical wird ein jährliches Gewinn- und Umsatzwachstum von 27% bzw. 118.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 29% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -41.1% betragen.

Wichtige Informationen

27.0%

Wachstumsrate der Gewinne

29.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	118.4%
Zukünftige Eigenkapitalrendite	-41.1%
Analystenabdeckung	Low
Zuletzt aktualisiert	08 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OTCPK:KNTP.F - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	388	-615	-597	-1,016	1
12/31/2024	103	-800	-824	-1,145	1
12/31/2023	N/A	-1,061	-390	-388	N/A
9/30/2023	N/A	-854	-437	-427	N/A
6/30/2023	N/A	-648	-484	-467	N/A
3/31/2023	N/A	-801	-736	-714	N/A
12/31/2022	N/A	-954	-989	-961	N/A
9/30/2022	17	-995	-1,192	-1,144	N/A
6/30/2022	34	-1,035	-1,396	-1,328	N/A
3/31/2022	34	-938	-1,276	-1,190	N/A
12/31/2021	34	-842	-1,157	-1,051	N/A
9/30/2021	17	-740	-960	-851	N/A
6/30/2021	N/A	-639	-763	-650	N/A
3/31/2021	N/A	-573	-620	-516	N/A
12/31/2020	N/A	-508	-477	-381	N/A
9/30/2020	N/A	-419	-430	-341	N/A
6/30/2020	N/A	-330	-382	-301	N/A
3/31/2020	N/A	-281	-342	-264	N/A
12/31/2019	N/A	-233	-302	-228	N/A
12/31/2018	1	-108	-134	-115	N/A
12/31/2017	0	-46	-57	-45	N/A
9/30/2017	0	-41	N/A	-36	N/A
6/30/2017	0	-35	N/A	-27	N/A
3/31/2017	1	-45	N/A	-21	N/A
12/31/2016	1	-54	N/A	-15	N/A
12/31/2015	N/A	-11	N/A	-13	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KNTP.F wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: KNTP.F wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: KNTP.F wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: KNTP.FDie Einnahmen des Unternehmens (118.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: KNTP.FDie Einnahmen des Unternehmens (118.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: KNTP.F wird voraussichtlich in 3 Jahren unrentabel sein.

Kintor Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 20, 2024

Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint

Kintor Pharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA

Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia

Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia

Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China

Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China

Kintor Pharmaceutical Limited to Report First Half, 2023 Results on Aug 28, 2023

Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 15, 2023

Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

Kintor Pharmaceutical Limited Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematological Malignancies in China

Kintor Pharmaceutical Limited Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound

Kintor Pharmaceutical Limited has completed a Follow-on Equity Offering in the amount of HKD 517.6 million.

Kintor Pharmaceutical Limited Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met

Kintor Pharmaceutical Limited Announces Top-Line Results of Phase I Clinical Trial of Gt20029 in China

Kintor Pharmaceutical Limited Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of Gt20029 in the U.S

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX 826 for Acne Vulgaris in China

Kintor Pharmaceutical Limited Announces Publication of Phase Ib Data from Pruxelutamide for Ar+ Mbc in Ejc

Kintor Pharmaceutical Limited to Report First Half, 2022 Results on Aug 29, 2022

Kintor Pharmaceutical Limited Completes Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the Us

Kintor Pharmaceutical Limited, Annual General Meeting, Jun 30, 2022

Kintor Pharmaceutical Limited Announces Board Changes

Kintor Pharmaceutical Limited Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma

Kintor Pharmaceutical Limited Announces Top-Line Results of the Phase III MRCT of Proxalutamide in Outpatients with Mild to Moderate Covid-19

Kintor Pharmaceutical Limited Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Aga in Female Patients

Kintor Pharma Limited Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US

Kintor Pharmaceutical Limited Announces Executive Changes

Kintor Pharma Announces First Patient Dosing in China in Phase III Clinical Trial of Proxalutamide for the Treatment of COVID-19 Outpatients

Kintor Pharmaceutical Limited Announces Dosing of First Subject in US Phase I Clinical Trial of GT20029 for Androgenic Alopecia and Acne

Kintor Pharma Announces Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826

Kintor Pharmaceutical Limited Announces First Patient Dosing of Phase III Clinical Trial of KX-826 (Pyrilutamide) for Treating Androgenic Alopecia Patients in China

Kintor Pharmaceutical Limited Provides Update Interim Analysis for Phase III Study of Proxalutamide for Patients with Mild to Moderate Covid-19 Symptoms

Kintor Pharmaceutical Limited Receives IND Clearance by NMPA for KX-826

Kintor Pharmaceutical Limited Announces the Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized Covid-19 Patients

Kintor Pharmaceutical Limited Announces Primary Endpoint of Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia

Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay

Kintor Pharmaceutical Limited Announces Investigational New Drug (IND) Clearance by the US FDA for GT20029 for Androgenetic Alopecia and Acne Vulgaris

Kintor Pharmaceutical Announces FDA Greenlighted Pyrilutamide's Phase II Clinical Trial for Androgenetic Alopecia in the US

Kintor Pharmaceutical Limited Receives Approval from Razilian Health Regulatory Agency in the Phase III Clinical Trial of Proxalutamide for Treatment of Male Patients with Mild to Moderate COVID-19 Illness

FDA Approves the Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalised COVID-19 Patients

Kintor Pharmaceuticals Announces Successful Proxalutamide COVID-19 Phase III Clinical Trial Initiation and Patient Dosing in U.S

Kintor Pharmaceutical Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Kintor Pharmaceutical Limited Announces to Release the Results of the Clinical Trial of Proxalutamide for the Treatment of Hospitalised COVID-19 Patients

Kintor Pharmaceutical Limited Receives Approval from US Food and Drug Administration for Proxalutamide's Phase III COVID-19 Clinical Trial

Kintor Pharmaceutical Limited Announces Completion of Patients' Recruitment for Proxalutamide's Covid-19 Hospitalised Study

US FDA Approves Kintor Pharmaceutical Limited's Investigational New Drug Application of GT90001's Phase II Clinical Trial for Advanced HCC

Kintor Pharmaceutical Limited Announces Investigational New Drug Application of GT20029 for Androgenetic Alopecia and Acne Vulgaris Indications

Kintor Pharmaceutical Limited Announces Approval of Clinical Trial of Proxalutamide's Treatment of Hospitalized COVID-19 Patients

Kintor Pharmaceutical Limited Provides Final Results for Male Patients and Interim Results for Female Patients from the Clinical Trial of Proxalutamide for the Treatment of COVID-19

Kintor Pharmaceutical Limited Announces Completion of Patients Enrolment for Pyrilutamide (KX-826)'s Phase II Clinical Trial for Indication of Androgenetic Alopecia in the PRC

Kintor Pharmaceutical Limited Announces Board and Committee Changes

Kintor Proxalutamide's Covid-19 Clinical Trial Shows Significant Reduction in Hospitalization and Ventilation Rates

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken